For those of us still sitting down and watching this thread every day every month getting very little information from our company, I thought I should probably inform fellow shareholders that Invion have sponsored an Abstract A6500 at the American Thoracic Society conference currently on in San Francisco. Under the category ' Reducing Harms of Tobacco use', the conclusion
'Nadolol is well tolerated for smoking cessation in this difficult to treat population and demonstrated a trend towards reduction in smoking rates especially those subjects with an elevated MUC5AC in their sputum'
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.015(12.0%) |
Mkt cap ! $9.320M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 10.5¢ | $24.18K | 211.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 28316 | 1 |
View Market Depth
| Last trade - 15.59pm 25/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |